7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,433.51

+115.60

+0.15%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Nasdaq Real Time Price USD

Biodexa Pharmaceuticals Plc (BDRX)

3.4300 -0.4700 (-12.05%)

At close: October 30 at 4:00:00 PM EDT

3.1500 -0.2800 (-8.16%)

After hours: October 30 at 7:28:55 PM EDT

Loading Chart for BDRX

Chart Range Bar

Interval:

In partnership with ChartIQ

Biodexa Reaches 100-Patient Enrollment Milestone in Phase 3 Serenta Trial as Key Analysis Timeline Accelerates

Biodexa Reaches 100-Patient Enrollment Milestone in Phase 3 Serenta Trial as Key Analysis Timeline Accelerates

Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP

Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP

Interim results for the six months ended June 30, 2026

Interim results for the six months ended June 30, 2026

Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP

Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP

Result of Annual General Meeting

Result of Annual General Meeting

Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants

Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants

Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress

Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress

Postponement and Re-scheduling of Annual General Meeting

Postponement and Re-scheduling of Annual General Meeting

BDRX: Enrollment in Phase 3 SERENTA Trial Reaches 92 Patients

BDRX: Enrollment in Phase 3 SERENTA Trial Reaches 92 Patients

BDRX: Expanding Phase 3 SERENTA Trial into Canada; 73 Patients Enrolled Thus Far

BDRX: Expanding Phase 3 SERENTA Trial into Canada; 73 Patients Enrolled Thus Far

The Longview: Fireside Chat with Biodexa CEO Stephen Stamp

The Longview: Fireside Chat with Biodexa CEO Stephen Stamp

Mobilize your Website

View Site in Mobile | Classic

Share by: